Omega-3 fatty acids for the treatment of cancer cachexia: Issues in designing clinical trials of dietary supplements

Journal of Alternative and Complementary Medicine

Volumn 11, Issue 6, 2005, Pages 1039-1046

  Harle, Lindsey ^a   Brown, Todd ^b   Laheru, Daniel ^b   Dobs, Adrian S ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AAFA; ANABOLIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO;

ALTERNATIVE MEDICINE; BODY WEIGHT; CACHEXIA; CANCER CACHEXIA; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG CONTAMINATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCOAGULABILITY; LEAN BODY WEIGHT; LIFE EXPECTANCY; LIPID COMPOSITION; METHODOLOGY; OUTCOMES RESEARCH; PANCREAS CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STANDARDIZATION; STEATORRHEA; WEIGHT REDUCTION;

CACHEXIA; CLINICAL TRIALS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; HUMANS; PANCREATIC NEOPLASMS; RESEARCH DESIGN;

EID: 31344441515     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2005.11.1039     Document Type: Review

References (43)

1. Wigmore SJ, Fearon KCH, Maingay JP, Ross JA. (1997) Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997;92:215-221.
2. Meydani SN, Lichtenstein AH, Cornwall S, et al. Immunological effects of National Cholesterol Education Panel Step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest 1993;92:105.
3. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-496.
4. Nixon DW, Heymsfield SB, Cohen AE, et al. Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 1980;68:683-690.
5. Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-86.
6. Fearon KCH, Barber MD, Falconer JS, et al. Pancreatic cancer as a model: Inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 1999;23:584-588.
7. Wigmore SJ, Fearon KC, Sangster K, et al. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 2002;21:881-886.
8. Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325-331.
9. Barber MD, McMillan DC, Preston T, et al. Metabolic response to feeding n weight-losing pancreatic cancer patients and its modulation by a fish oil enriched nutritional supplement. Clin Sci 2000;98:389-399.
10. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12:S27-S30.
11. Alter CL. Palliative and supportive care of patients with pancreatic cancer. Semin Oncol 1996;23:229-240.
12. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999;5:3942-3947.
13. Wang MY, Abbruzzese JL, Friess H, et al. DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res 1998;58:34-41.
14. Li D, Firozi PF, Zhang W, et al. DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 2002;513:37-48.
15. Puscas I, Baican M, Coltau M, et al. Erythrocyte superoxide dismutase activity in patients with digest cancer: Adjuvant diagnosis test. Cancer Lett 1999;143:95-98.
16. Meydani M, Natiello F, Goldin B, et al. Effect of long-term fish oil supplementation on vitamin E status and lipid peroxidation in women. J Nutr 1991;121(4):484-491.
17. Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: Emerging evidence for their role as risk modifiers. Carcinogenesis 1999;20:2209-2218.
18. Yang P, Chan D, Felix E, et al. Formation and antiproliferative effect of prostaglandin E3 from eieosapentaenoic acid in human lung cancer cells. J Lipid Res 2004;45:1030-1039.
19. Pinto JA, Folador A, Bonato SJ, et al. Fish oil supplementation in F1 generation associated with naproxen, clenbuterol and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats. J Nutr Biochem 2004;15:358-365.
20. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab 1998;12:379-390.
21. Wigmore SJ, Barber MD, Ross JA, et al. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000;36:177-184.
22. Kinsel JF, Straus SE. Complementary and alternative therapeutics: Rigorous research is needed to support claims. Annu Rev Pharmacol Toxicol 2003;43:463-484 [Epub 2002 Jan 10].
23. Bass IS, Raubicheck CJ. Marketing Dietary Supplements. Washington, DC: Food and Drug Law Institute, 2000.
24. Harris IM. Regulatory and ethical issues with dietary supplements. Pharmacotherapy 2000;20:1295-1302.
25. Berman JD, Straus SE. Implementing a research agenda for complementary and alternative medicine. Annu Rev Med 2004;55:239-254.
26. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;129:18-26.
27. Connor WE, DeFrancesco CA, Connor SL. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann N Y Acad Sci 1993, 14;683:16-34.
28. Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids 2000;63:351-362.
29. Sun D, Krishnan A, Zaman K, et al. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res 2003;18:1206-1216.
30. Zimmer L, Delpal S, Guilloteau D, et al. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett 2000;284:25-28.
31. Ohishi K, Ueno R, Nishino S, et al. Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988;23:326-334.
32. Bagga D, Wang L, Farias-Eisner R, et al. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 2003;100:1751-1756.
33. Yang P, Chan D, Felix E, et al. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res 2004;45:1030-1039 [Epub 2004 Mar 01].
34. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 2004;23:71-78.
35. Novak TE, Babcock TA, Jho DH, et al. NF-kappa B inhibition by ornega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 2003;284:L84-L89.
36. Delion S, Chalon S, Guilloteau D, et al. Alpha-linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotonerigic neurotransmission in the rat frontal cortex. J Neurochem 1996;66:1582-1591.
37. Hamilton L, Greiner R, Salem N Jr, Kim HY. n-3 Fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids 2000;35:863-869.
38. Ohata T, Fukuda K, Takahashi M, et al. Suppression of nitric oxide production in lipopolysaccharide-stimulated macrophage cells by omega 3 polyunsuturuted fatty acids. Jpn J Cancer Res 1997;88:234-237.
39. Jeyarajah DR, Kielar M, Penfield J, Lu CY. Docosahexaenoic acid, a component of fish oil, inhibits nitric oxide production in vitro. J Surg Res 1999;83:147-150.
40. Takahashi M, Tsuboyama-Kasaoka N, Nakatani T, et al. Fish oil feeding alters liver gene expressions to defend against PPA-Ralpha activation and ROS production. Am J Physiol 2002;282:G338-G348.
41. Okumura T, Fujioka Y, Morimoto S, et al. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability. Am J Med Sci 2002;324:247-253.
42. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89:1763-1773.
43. Nahin RL, Straus SE. Research into complementary and alternative medicine: Problems and potential. BMJ 2001;322:161-254.